Suppr超能文献

化疗和生物疗法在神经内分泌肿瘤治疗中的应用

Chemotherapy and biotherapy in the treatment of neuroendocrine tumours.

作者信息

Oberg K

机构信息

Department of Endocrine Oncology, Medical Sciences, Internal Medicine, Uppsala University Hospital, Sweden.

出版信息

Ann Oncol. 2001;12 Suppl 2:S111-4. doi: 10.1093/annonc/12.suppl_2.s111.

Abstract

The medical treatment of neuroendocrine GEP tumours must be based on the growth properties of the tumour. Medical treatment includes chemotherapy, somatostatin analogues and alpha interferons. Chemotherapy has been particularly active in patients with high proliferating neuroendocrine tumours such as endocrine pancreatic tumours and lung carcinoids. Streptozotocin-based combinations including 5-flourouracil and doxorubicin have generated partial remissions in 40%-60% of the patients giving a median survival of about two years in patients with advanced disease. Cisplatinum plus etoposide have demonstrated significant antitumour effects in anaplastic endocrine pancreatic tumours and lung carcinoids. However, in low proliferating tumours such as classical midgut carcinoids the response rates with the same combinations of cytotoxic agents have only generated short lasting responses in less than 10% of patients. In these patients, biological treatment has been of benefit. Alpha interferon at doses of 3-9 million units three to seven times per week subcutaneously, has given biochemical response rates of 50% and significant tumour reduction in about 15% of patients with long duration, up to three years. Somatostatin analogues have been widely used in the treatment of neuroendocrine gut and pancreatic tumours. The currently available somatostatin analogues particularly bind somatostatin receptor 2 and 5 and with low affinity also receptor subtype 3. Octreotide is registered in most countries for the treatment of patients with carcinoid syndrome and also VIP and glucagon producing tumours. Regular octreotide at standard doses of 100-300 microg/day gives symptomatic responses in a medium of 60% of patients and biochemical responses in up to 70% of patients. Significant tumour responses are rare, less than 5%. Long-acting formulations of somatostatin analogues have been of significant benefit for the patients with similar response rates as for regular formulations. The quality of life has been significantly improved by using the long-acting formulations.

摘要

神经内分泌胃肠胰肿瘤的医学治疗必须基于肿瘤的生长特性。医学治疗包括化疗、生长抑素类似物和α干扰素。化疗在高增殖性神经内分泌肿瘤患者中表现出特别显著的效果,如内分泌胰腺肿瘤和肺类癌。以链脲佐菌素为基础的联合化疗方案,包括5-氟尿嘧啶和阿霉素,使40%-60%的患者出现部分缓解,晚期疾病患者的中位生存期约为两年。顺铂加依托泊苷在间变性内分泌胰腺肿瘤和肺类癌中显示出显著的抗肿瘤作用。然而,在低增殖性肿瘤如经典的中肠类癌中,相同的细胞毒性药物联合使用时,缓解率仅在不到10%的患者中产生短暂的反应。在这些患者中,生物治疗已显示出益处。皮下注射剂量为300万至900万单位、每周三至七次的α干扰素,可使50%的患者出现生化反应,约15%的患者肿瘤显著缩小,持续时间长达三年。生长抑素类似物已广泛应用于神经内分泌肠道和胰腺肿瘤的治疗。目前可用的生长抑素类似物特别与生长抑素受体2和5结合,对受体亚型3的亲和力较低。奥曲肽在大多数国家已注册用于治疗类癌综合征患者以及产生血管活性肠肽和胰高血糖素的肿瘤患者。标准剂量为每日100-300微克的常规奥曲肽,可使60%的患者出现症状缓解,高达70%的患者出现生化反应。显著的肿瘤反应很少见,不到5%。生长抑素类似物的长效制剂对患者有显著益处,其反应率与常规制剂相似。使用长效制剂可显著改善生活质量。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验